Browse N L, Jarrett P E, Morland M, Burnand K
Br Med J. 1977 Aug 13;2(6084):434-5. doi: 10.1136/bmj.2.6084.434.
Fourteen patients with longstanding lipodermatosclerosis of their lower legs, secondary to venous disease in 11, were treated for three months with stanozolol, a drug that enhances fibrinolytic activity. No other treatment was given and no change made in existing treatment. All the patients improved. Two were cured in three months, three were able to stop treatment in the next three to 11 months, and the other nine continued to improve. Fibrinolytic enhancement, with stanozolol, seems to be a worthwhile addition to the treatment of venous liposclerosis and deserves further study.
14名小腿患有长期脂性皮肤硬化症的患者，其中11例继发于静脉疾病，接受司坦唑醇治疗3个月，司坦唑醇是一种可增强纤溶活性的药物。未给予其他治疗，现有治疗也未改变。所有患者均有改善。2例在3个月内治愈，3例在接下来的3至11个月内能够停止治疗，另外9例持续改善。司坦唑醇增强纤溶活性，似乎是静脉性脂肪硬化症治疗中一项值得添加的治疗方法，值得进一步研究。
